A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients.

Trial Profile

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2018

At a glance

  • Drugs Rufinamide (Primary)
  • Indications Lennox-Gastaut syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 27 Apr 2018 Results from NCT01151540, NCT01405053, NCT01146951 and 2 other studies, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2016 Post-hoc subgroup analysis (n=31) of this trial were presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 08 Mar 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov (Parent trial:NCT01146951).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top